✦ LIBER ✦

Effect of prothymosin α and its mutants on the activity of the p53 tumor suppressor

✍ Scribed by N. I. Zakharova; V. V. Sokolov; V. V. Roudko; S. V. Melnikov; A. B. Vartapetian; A. G. Evstafieva

Book ID: 110174597
Publisher: SP MAIK Nauka/Interperiodica
Year: 2008
Tongue: English
Weight: 260 KB
Volume: 42
Category: Article
ISSN: 0026-8933
DOI: 10.1134/s002689330804016x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The effects of wild-type p53 tumor suppr

The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth

✍ Craig Cadwell; Gerard P Zambetti 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 336 KB

Activation of the p53 tumor suppressor p

Activation of the p53 tumor suppressor protein

✍ Karen H Vousden 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 347 KB

Inhibition of the putative tumor suppres

Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53

✍ Loging, W Troy; Reisman, David 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 320 KB

Effect of Phosphorylation on Tetrameriza

Effect of Phosphorylation on Tetramerization of the Tumor Suppressor Protein p53

✍ Kazuyasu Sakaguchi; Hiroshi Sakamoto; Dong Xie; John W. Erickson; Marc S. Lewis; 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 556 KB

Construction of Chimeric Tumor Suppresso

Construction of Chimeric Tumor Suppressor p53 Resistant to the Dominant-Negative Interaction with p53 Mutants

✍ V. P. Almazov; A. A. Morgunkova; V. N. Kalinin; B. P. Kopnin; V. S. Prasolov; P. 📂 Article 📅 2002 🏛 SP MAIK Nauka/Interperiodica 🌐 English ⚖ 150 KB

Pharmacogenomics of the p53 tumor suppre

Pharmacogenomics of the p53 tumor suppressor and its role in cancer chemoresistance

✍ Suxing Liu; W. Robert Bishop; Bimal Dasmahapatra; Yaolin Wang 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 214 KB 👁 1 views

## Abstract Drug resistance remains a key obstacle to successful cancer treatment. The implementation of pharmacogenomics is widely proclaimed as a route to revolutionize the face of cancer therapy. Here we discuss the pharmacogenomics of the p53 tumor suppressor and its role in cancer chemosensiti